Ma Xiaoli, Huang Dongsheng, Zhao Weihong, Sun Liming, Xiong Hao, Zhang Yi, Jin Mei, Zhang Dawei, Huang Cheng, Wang Huanmin, Zhang Weiping, Sun Ning, He Lejian, Tang Jingyan
Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University Beijing 100045, China.
Department of Pediatrics, Beijing Tong Ren Hospital Beijing 100730, China.
Int J Clin Exp Med. 2015 Oct 15;8(10):17196-205. eCollection 2015.
Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children. We have retrospectively explored the treatment results of childhood RMS and identified prognostic factors in multicenter in China, in order to lay the foundation for further multicenter study.
This retrospective study was carried out analyzing the medical records of 161 patients with the pathological diagnosis of RMS from January, 2001 to February, 2014 at 5 large cancer centers in China. The data was reviewed clinico-epidemiological factors. Age, gender, histology type, primary site, tumor size, intergroup rhabdomyosarcoma study (IRS) group and results of treatments were evaluated. Patients were followed up to Dec 31, 2014.
The median age of our patients was 51 months. 10.5% of our patients were infants. The genitourinary system was the most common primary site of tumor (43.5%). The proportion of primary site of head and neck except parameningeal, at 28.2% (42 cases), while the proportion of parameningeal region was 4.6% (7 cases). The histological findings were as follows: 130 cases (80.7%) with embryonal, 19 cases (11.9%) with alveolar and 5 cases (3.1%) with botryoid type. According to the classification system of the IRS group, 1 case (0.6%) was group I, 54 cases (33.5%) were group II, 46 cases (28.6%) were group III and 60 cases (37.3 %) were group IV. 149 patients were treated and followed-up regularly, Patients in Beijing children's hospital (n=95) were enrolled in IRS-II/COG-D9803, D9802 protocols. while the other patients (n=54) started on treatment according to Chinese Anti-cancer Association protocol. There were median time of 51 months for following up, 60 occurred event. The ten-year event free survival rate was 53.4±5.1%, overall survival was 65.3±6.3%. The relations between outcome and age (0.046), primary site (0.022), pathologic subtype (0.013), tumor size (0.008) and IRS group (P=0.000) were associated significantly with event free survival. Among the variables, age (P=0.028) and IRS group (P=0.000) were associated significantly with overall survival. Multivariate analysis showed that overall survival for RMS was dependent on IRS group (P=0.026).
The epidemiological characteristics of our patients are quite similarly to the worldwide data. Except for the higher prevalence of group IV in our patients and the higher percentage of patients with primary tumor site in the genitourinary system, this study showed that overall survival for RMS is depended on disease group.
横纹肌肉瘤(RMS)是儿童中最常见的软组织肉瘤。我们回顾性地探讨了中国多中心儿童RMS的治疗结果并确定了预后因素,以便为进一步的多中心研究奠定基础。
这项回顾性研究分析了2001年1月至2014年2月期间中国5家大型癌症中心161例经病理诊断为RMS患者的病历。回顾了临床流行病学因素。评估了年龄、性别、组织学类型、原发部位、肿瘤大小、横纹肌肉瘤协作组(IRS)分组及治疗结果。对患者随访至2014年12月31日。
我们患者的中位年龄为51个月。10.5%的患者为婴儿。泌尿生殖系统是最常见的肿瘤原发部位(43.5%)。头颈部除脑膜旁外的原发部位比例为28.2%(42例),而脑膜旁区域的比例为4.6%(7例)。组织学结果如下:胚胎型130例(80.7%),肺泡型19例(11.9%),葡萄簇型5例(3.1%)。根据IRS组分类系统,I组1例(0.6%),II组54例(33.5%),III组46例(28.6%),IV组60例(37.3%)。149例患者接受了正规治疗和随访,北京儿童医院的患者(n = 95)参加了IRS-II/COG-D9803、D9802方案,而其他患者(n = 54)根据中国抗癌协会方案开始治疗。中位随访时间为51个月,发生事件60例。十年无事件生存率为53.4±(5.1)%,总生存率为65.3±(6.3)%。无事件生存率与年龄(0.046)、原发部位(0.022)、病理亚型(0.013)、肿瘤大小(0.008)和IRS组(P = 0.000)显著相关。在这些变量中,年龄(P = 0.028)和IRS组(P = 0.000)与总生存率显著相关。多因素分析显示RMS的总生存率取决于IRS组(P = 0.026)。
我们患者的流行病学特征与全球数据非常相似。除了我们患者中IV组的患病率较高以及泌尿生殖系统原发肿瘤部位的患者百分比更高外,本研究表明RMS的总生存率取决于疾病分组。